What price ranges applied to the Orthofix (OFIX) share sales?

The filing notes weighted average prices, with March 4 sales executed between $12.80 and $13.03 per share and March 5 sales executed between $12.48 and $12.72 per share, reflecting multiple transactions within those ranges.

Orthofix Medical (OFIX) exec sells shares for RSU tax cover

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Orthofix Medical Inc. President, Global Spine, Max Reinhardt reported selling 2,133 shares of common stock in open-market transactions on March 4 and March 5, 2026. The shares were sold solely to satisfy tax withholding obligations from restricted stock unit settlement under a pre-approved sell-to-cover mandate, with no discretion exercised by him. After these sales, he directly held 25,348 shares, including 19,417 restricted stock units.

Insider Trade Summary

Net Seller: 2,133 shares ($27,166)

Net Sell 2 txns

Insider REINHARDT MAX

Role President, Global Spine

Sold 2,133 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,053	$12.5508	$13K
Sale	Common Stock	1,080	$12.9163	$14K

Holdings After Transaction: Common Stock — 25,348 shares (Direct)

Footnotes (1)

Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. Includes 19,417 previously reported restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/06/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REINHARDT MAX

(Last)

(First)

(Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE

75056

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, Global Spine

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		S⁽¹⁾		1,080	D	$12.9163⁽²⁾	26,401⁽³⁾	D
Common Stock	03/05/2026		S⁽¹⁾		1,053	D	$12.5508⁽⁴⁾	25,348⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 19,417 previously reported restricted stock units.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ J. Andres Cedron, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Orthofix (OFIX) disclose in this Form 4?

Orthofix reported that executive Max Reinhardt sold 2,133 shares of common stock. The sales occurred on March 4 and 5, 2026, and were made in the open market to cover tax withholding tied to restricted stock unit settlement.

Who is Max Reinhardt in relation to Orthofix (OFIX)?

Max Reinhardt is Orthofix’s President, Global Spine. As a senior executive, his equity transactions in company stock must be reported on Form 4, providing transparency into changes in his beneficial ownership position over time.

How many Orthofix (OFIX) shares did Max Reinhardt sell and at what prices?

He sold 1,080 shares at a weighted average price of $12.9163 on March 4 and 1,053 shares at a weighted average price of $12.5508 on March 5, 2026, all in open-market transactions as disclosed.

Were Max Reinhardt’s Orthofix (OFIX) stock sales discretionary trades?

No. The filing states the shares were sold to satisfy tax withholding obligations from restricted stock unit settlement under a pre-existing sell-to-cover requirement approved by the board committee, and the sale occurred without any discretion by Reinhardt.

How many Orthofix (OFIX) shares does Max Reinhardt hold after these sales?

After the reported transactions, Max Reinhardt directly owned 25,348 shares of Orthofix common stock. This amount includes 19,417 previously reported restricted stock units, showing his remaining equity exposure to the company.